LATAM: Entitled Improving Biomarker-Driven Care in Ovarian & Uterine Cancer
An IGCS and AstraZeneca partnership to improve biomarker-driven care for ovarian and uterine cancer in Latin America
Advancing Gynecologic Cancer Care in Latin America
IGCS and AstraZeneca are working together to strengthen gynecologic cancer care across Latin America through the program Improving Biomarker-Driven Care in Ovarian & Uterine Cancer. Building on the insights of the IGCS Latin America survey, the program aims to close the gap between the latest evidence and everyday practice, so more patients in the region can benefit from timely, biomarker-driven care.
Through a range of educational activities, both virtual and in person, IGCS will bring together regional and international experts to share knowledge, discuss real-world cases and promote multidisciplinary collaboration. The goal is to give healthcare professionals across Latin America practical tools and resources they can apply in their own institutions. Stay tuned for upcoming opportunities to join us!

astrazenecaigsc
Summary
Availability:
On-Demand
Cost:
FREE
Contains (2)
Molecular classification, biomarker testing, and access to modern therapies in endometrial cancer across Latin America: an International Gynecologic Cancer Society survey
LATAM Biomarker-Driven Gyn Oncology: From Evidence to Access | IGCS Symposium, EVA 2026 São Paulo
Recommended